Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-05-13
2010-12-07
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S307000, C546S150000, C544S128000
Reexamination Certificate
active
07846930
ABSTRACT:
Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3receptor and/or serotonin transporter modulators useful in the treatment of histamine H3receptor- and/or serotonin-mediated diseases.
REFERENCES:
patent: 4113869 (1978-09-01), Gardner et al.
patent: 2006/0194837 (2006-08-01), Carruthers et al.
patent: 2006/0287292 (2006-12-01), Carruthers et al.
patent: 2006/0293316 (2006-12-01), Apodaca et al.
patent: WO 01/32624 (2001-05-01), None
patent: WO 2006/066197 (2006-06-01), None
Bagshawe, K.D.: “Antibody-Directed Enzyme Prodrug Therapy: A Review”; Drug Devel. Research (1995) 34: 220-230.
Barbier, A.J. et al.: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist; British J. of Pharmacology (2004) 143: 649-661.
Barnes, J.C. et al.: The Selective Histamine H3 Receptor Antagonist thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in Vivo. Soc. Neurosci. Abstr. (1993) 19: 1813.
Beasley, C.M., Jr., MD, et al.: “Adverse Events and Treatment Discontinuations in Clinical Trials of Fluoxetine in Major Depressive Disorder: An Updated Meta-Analysis”; Clinical Therapeutics (2000) 22(11): 1319-1330.
Berge, S.M. et al.: “Pharmaceutical Salts”; J. of Pharmaceutical Sciences (1977) 66(1): 1-19.
Bertolini, G. et al.: “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, A Potent Immunosuppressive Drug”; J. Med. Chem. (1997) 40: 2011-2016.
Bodor, N.: Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems; Advances in Drug Research (1984) 13: 255-331.
Chen, Z.: “Effect of histamine H3-receptor antagonst clobenpropit on spatial memory of radial maze performance in rats”; Acta Pharmacol Sin (2000) 21(10): 905-910.
Fava, G.A. et al.: “Residual symptoms in depression: An emerging therapeutic target”; Prog. Neruo-Psychopharmacology & Biol. Psychiatry (2002) 26(6): 1019-1027.
Fleisher, D. et al.: “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs”; Adv. Drug Del. Rev. (1996) 19: 115-130.
Fox, G.B. et al.: “Effects of histamine H3receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup”; Behavioural Brain Research (2002) 131: 151-161.
Hill, S.J. et al.: “International Union of Pharmacology. XIII. Classification of Histamine Receptors”; Pharmacol. Rev. (1997) 49(3): 253-278.
Jané-Lopis, E. et al.: “Predictors of efficacy in depression prevention programmes”; Br. J. Psychiatry (2003) 183: 384-397.
Keith, J.M. et al.: “Dual serotonin transporter inhibitor/histamine H3 antagonists: Development of rigidified H3 pharmacophores”; Bioorg. & Med. Chem. Letters (2007) 17(19): 5325-5329.
Lamberti, C. et al.: “Antidepressant-like effects of endogenous histamine and of two histamine H1receptor agonists in the mouse forced swim test”; British J. of Pharmacology (1998) 123(7): 1331-1336.
Leurs, R. et al.: The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3 Receptor; Prog. Drug. Res. (1995) 45: 107-165.
Lintunen et al.: “Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H3receptor mechanisms1”; FASEB Journal (2001) 15(6): 1074-1076.
Machidori, H. et al.: Zucker Obese Rats: Defect in Brain Histamine Control of Feeding; Brain Res. (1992) 590: 180-186.
Miyazaki, S. et al.: “Effects of Thioperamide on the Cholinergic System and the Step-Through Passive Avoidance Test in Mice”; Meth Find Exp Clin Pharmacol (1995) 17(10): 653-658.
Miyazaki, S. et al.: “Effects of Thioperamide, a Histamine H3-receptor Antagonist, on a Scopolamine-induced Learning Deficit Using an Elevated Plus-maze Test in Mice”; Life Sciences, (1995) 57(23): 2137-2144.
Monti, J.M. et al.: “Effects of selective activation or blockade of the histamine H3receptor on sleep and wakefulness”; Eur. J. of Pharmacology (1991) 205: 283-287.
Morisset, S. et al.: High Constitutive Activity of Native H3 Receptors Regulates Histamine Neurons in Brain. Nature (Dec. 2000) 408: 860-864.
Nierenberg, A.A., MD et al.: “Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine”; J. Clin. Psychiatry (Apr. 1999) 60: 221-225.
Orsetti, M. et al.: “Histamine H3-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task”; Elsevier Behavioural Brain Research (2001) 124(2): 235-242.
Panula, P. et al.: Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease. Soc. Neurosci. Abstr. (1995) 21: 1977.
Perez-Garcia, C. et al.: “Effects of histamine H3receptor ligands in experimental models of anxiety and depression”; Psychopharmacology (1999) 142(2): 215-220.
Robinson, R.P. et al.: “Discovery of the Hemifumarate and (α-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group”; J. Med. Chem. (1996) 39: 10-18.
Schlicker, E. et al.: The Moderate Affinity of Clozapine at H3 Receptors Is Not Shared by Its Two Major Metabolites and by Structurally Related and Unrelated Atypical Neuroleptics. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 353: 290-294.
Shan, D. et al.: “Prodrug Strategies Based on Intramolecular Cyclization Reactions”; J. of Pharm. Sciences (Jul. 1997) 86(7): 765-767.
Stark, H. et al.: Developments of Histamine H3-Receptor Antagonists. Drugs Future (1996) 21(5): 507-520.
Yokoyama, H. et al.: Effect of Thioperamide, a Histamine H3Receptor Antagonist, on Electrically Induced Convulsions in Mice. Eur. J. Pharmacol. (1993) 234: 129-133.
Zajecka, J.M., MD: “Clinical Issues in Long-Term Treatment With Antidepressants”; J. Clin. Psychiatry (2000) 61 (Suppl. 2): 20-25.
Bundgaard et al Design of Prodrugs Ed H Bundgaard Elsevier 1985.
Larsen et al Design and Application of Prodrugs Drug Design and Development Krogsgaard-Larsen et al Eds Harswood Academic Publishers 1991.
Leurs et al The Histamine H3 Receptor—A Target for New Drugs Leurs r. and Timmernam H. Eds Elsevier 1998.
Stahl et al Handbook of Pharmaceutical Salts, Properties Selection and Use Stahl and Wermuth Eds Wiley-VCH and VHCA Zurich 2002.
Barbier, et al. “Pharmacological Characterization of JNJ-28583867, A Histamine H3 Receptor Antagonist and Serotonin Reuptake Inhibitor”. European Journal of Pharmacology, Amsterdam, NL., vol. 576, No. 1-3, Oct. 19, 2007, pp. 43-54.
PCT International Search Report for PCT/US2008/063516 dated Sep. 2, 2008.
Anderson Rebecca L
Atkins Michael J.
Janssen Pharmaceutica NV
LandOfFree
Diaryl-substituted tetrahydroisoquinolines as histamine H 3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaryl-substituted tetrahydroisoquinolines as histamine H 3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaryl-substituted tetrahydroisoquinolines as histamine H 3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189697